GSK3B and breast carcinoma: (5) As shown in Figure 6(a), the regulation confirmed by Q-PCR in treatment process of CGA for EMT-6 breast cancer indicates groups of CGA in each dose and DX can activate expression of GSK-3β, especially the CGA 20 mg/kg group and the DX group can significantly upregulate GSK-3β (P < 0.05).